Effectiveness and management of ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian medicines agency (AIFA)

Saved in:

Bibliographic Details
Published in	Annals of hematology Vol. 102; no. 5; pp. 1257 - 1259
Main Authors	Breccia, Massimo, Olimpieri, Pier Paolo, Celant, Simone, Olimpieri, Odoardo Maria, Pane, Fabrizio, Iurlo, Alessandra, Summa, Valentina, Corradini, Paolo, Russo, Pierluigi
Format	Journal Article
Language	English
Published	Berlin/Heidelberg Springer Berlin Heidelberg 01.05.2023 Springer Nature B.V
Subjects	Antineoplastic Agents - adverse effects Hematology Humans Imidazoles - therapeutic use Letter to the Editor Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Medicine Medicine & Public Health Oncology Protein Kinase Inhibitors - adverse effects Pyridazines - adverse effects Registries
Online Access	Get full text
ISSN	0939-5555 1432-0584 1432-0584
DOI	10.1007/s00277-023-05168-8

More Information
Bibliography:	SourceType-Scholarly Journals-1 ObjectType-Correspondence-1 content type line 14 content type line 23
ISSN:	0939-5555 1432-0584 1432-0584
DOI:	10.1007/s00277-023-05168-8